3SBio Acquires Sirton Pharmaceuticals SpA

SHENYANG, China and VILLA GUARDIA, Italy, Jan. 26, 2015 /PRNewswire/-- 3SBio Inc., "3SBio", a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that on December 31, 2014, 3SBio acquired the entire share capital of Sirton Pharmaceuticals SpA ("Sirton") from First Shanghai Limited.

"Expanding 3SBio's footprint in key developed markets is a core strategic objective for 3SBio," commented Dr. Jing Lou, Chairman and Chief Executive Office of 3SBio Inc. He continued, "With a team of experienced professionals and a client base of leading pharmaceutical companies, Sirton provides 3SBio with a solid base to manufacture, develop and market pharmaceutical products in Europe. We look forward to working with Sirton's management team and clients to provide safe, affordable and innovative medicines to patients across Europe."
Mr. Giorgio Biella, Managing Director of Sirton, added, "My colleagues and I look forward to working with the team from 3SBio as we pursue our common goal of manufacturing high-quality medicines for international markets." He continued, "3SBio's proven R&D capabilities, global business development strategies, and strong financial position will complement Sirton's existing client relationships and manufacturing experience in Europe."

About Sirton Pharmaceuticals SpA
Sirton Pharmaceuticals SpA ("Sirton") is a pharmaceutical contract manufacturing company located in Villa Guardia, near Cuomo, Italy. Sirton produces injectable pharma products, including pre-filled syringes, liquid vials, freeze-dried vials and ampoules, and pharmaceutical development services including lyophilization process development, analytical method development and validation, stability studies and manufacturing of clinical study materials. Sirton's customers are leading international pharmaceutical companies, including Mylan, Sandoz, Sanofi Avenis France, Crinos and UCB Pharma. Sirton also develops and produces generic pharmaceutical products including zoledronic acid, through Ingenerics S.r.l, a joint venture with Tripharma S.p.A.
For more information visit www.sirton.it.

About 3SBio Inc.
3SBio is a fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China. Since its founding in 1993, 3SBio's R&D efforts have resulted in four NDAs for biological medicines, including TPIAO, the first rhTPO approved worldwide.
Pipeline candidates include Uricase PEG-20, a modified pegylated recombinant uricase from Candida utilis for the treatment of refractory gout and tumor lysis syndrome which has completed US Phase 1 trials; NuPIAO, a long-acting erythropoiesis-stimulating agent (ESA) for anemia associated with renal failure or chemotherapy and peri-operative blood cell mobilization which has received China FDA's approval to initiate clinical trials; SSS07, an anti-TNF monoclonal antibody for treating rheumatoid arthritis, psoriasis, and potentially other inflammatory diseases; Leukotuximab/SSS19, an anti-CD43/JL-1 monoclonal antibody for treating acute leukemia; and Tanibirumab/SSS23, a anti-VEGFR2 monoclonal antibody for treating solid tumors.

A new state-of-the-art mammalian biological manufacturing facility in Shenyang is the first and only rhEPO facility in China that conforms to both Chinese and European pharmacopeia standards. Planning is underway to develop monoclonal antibody manufacturing capabilities.

3SBio is China's leading specialist in nephrology and oncology supportive care with more than 600 sales professionals covering over 3,000 hospitals in key cities supported by a nationwide network of 120 distributors and logistics providers. EPIAO has been the top selling rhEPO product in China since 2002 with a market share over 40%.

Please visit www.3sbio.com for additional information.
3SBio Contact Information

Tan Bo
Chief Financial Officer
3SBio Inc.
B-13, Grand Place 5 Huizhong Road, Chaoyang District, Beijing, China 100101
Tel: +86 10 8489 2211
Fax: +86 10 8489 2951
Email: [email protected]

Jiang Fei, PhD
Director, Business Development
3SBio Inc.
Shenxin Building 801-802, 200 Ninghai Dong Rd, Huangpu District, Shanghai, China 200021
Tel: +86 186 4022 0510
Fax: +86 21 6374 4922
Email: [email protected]

Tom Folinsbee
Director, Corporate Development
3SBio Inc.
Unit 402 Fairmont House, No.8 Cotton Tree Drive, Admiralty Hong Kong
Tel: +852 8191 6991
Fax: +852 3007 9376
Email: [email protected]

Donald Wyatt
VP, Business Development & Alliance Management
3SBio Inc.
No. 3 A1, Road 10, Shenyang Economy & Technology Development Zone, Shenyang, China 110027
US Tel: +1 425 516 7491
China Tel: +86 138 1816 5538
Email: [email protected]

Sirton Pharmaceuticals SpA Contact Information
Giorgio Biella
Managing Director
Piazza XX Settembre, 2
22079 Villa Guardia
Como -- Italy
Tel: +39 031 385343
Fax: +39 031 385329
Email: [email protected]

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.